Activist investor Elliott Investment Management has acquired a stake in BP (NYSE:BP), aiming to enhance shareholder value. While the exact size of the stake remains undisclosed, Bloomberg reports it is "significant."
Elliott, known for its influence in corporate shakeups, sees BP as undervalued compared to its rivals. The British oil giant, with a market capitalization of $85.62 billion, is worth less than half of Shell (LON:SHEL), which stands at approximately $161 billion.
BP CEO Murray Auchincloss has been focusing on cost-cutting and strategic shifts to regain investor confidence. The company plans to reduce expenses by at least $2 billion by 2026 and recently announced the sale of a German refining site. Additionally, BP will cut over 5% of its global workforce. Auchincloss, who took over in 2023 following Bernard Looney’s abrupt departure, is set to outline his strategic vision at an investor event on February 26.
BP has warned that declining refining margins and maintenance costs could lower quarterly profits by up to $300 million. Other global refiners have also signaled weak near-term profitability due to margin downturns. The company will release its Q4 and full-year earnings on February 11.
Elliott, managing $70 billion in assets, has a history of pushing for major corporate transformations. It recently advocated for a breakup of Honeywell (NASDAQ:HON) and took a 3.2% stake in Anglo American (JO:AGLJ), following BHP Group’s takeover interest.
Neither Elliott nor BP has commented on the investment. However, with BP’s ongoing restructuring and Elliott’s track record in driving change, the oil major may soon face significant strategic shifts.


OpenAI AI Agent Swarm Behind Hugging Face Hack
Honda, Nissan Eye Shared Vehicle Software Platform by 2029
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question
Tempus AI Stock Soars 18% After Pelosi's Investment Disclosure
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Investors Brace for Market Moves as Trump Begins Second Term
China’s Growth Faces Structural Challenges Amid Doubts Over Data
Jefferies Lowers Ratings on Three Leading UK Industrial Stocks
Itochu Offers $1.56 Billion to Privatize Dentsu Soken
U.S. Condemns China's Dominance in Global Shipbuilding and Maritime Sectors
Ferrari Group to Launch IPO in Amsterdam, Targets Over $1 Billion Valuation
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook
Wall Street Rebounds as Investors Eye Tariff Uncertainty, Jobs Report
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat
European Stocks Rally on Chinese Growth and Mining Merger Speculation
Mercer International Stock Surges 45% on C$20 Million Canada Funding 



